September 22, 2020 -- IPA Europe, a subsidiary of ImmunoPrecise Antibodies, has expanded its foundational B cell Select platform for seamless integration into ImmunoPrecise's optimization and antibody developability profiling workflow.
With substantial investments, IPA Europe developed a second-generation platform that enables multispecies, target-interaction-based single B cell selection technology and subsequent single cell cloning for accelerated identification of comprehensive panels of diverse lead therapeutic antibodies.
The B cell Select platform enables interrogation of isolated B cells to analyze full organism antibody repertoires. The species independent platform can develop a range of antibodies, including any protein class, complex therapeutic target, post-translation modifications, and small molecules. The system generates monoclonal antibodies for B cell selection to accelerate the rate of the antibody discovery process.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
